Trial Profile
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 May 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms SEARCH
- Sponsors Bayer; Bayer HealthCare
- 30 May 2019 This trial has been completed in Greece, according to European Clinical Trials Database.
- 27 Jun 2018 This trial has been completed in Spain (end date: 2018-05-23)
- 07 Jun 2018 Status changed from active, no longer recruiting to completed.